Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial

BACKGROUND: Severe COVID-19 is characterised by inflammation and coagulation in the presence of complement system activation. We aimed to explore the potential benefit and safety of selectively blocking the anaphylatoxin and complement protein C5a with the monoclonal antibody IFX-1 (vilobelimab), in...

Descripción completa

Detalles Bibliográficos
Autores principales: Vlaar, Alexander P J, de Bruin, Sanne, Busch, Matthias, Timmermans, Sjoerd A M E G, van Zeggeren, Ingeborg E, Koning, Rutger, ter Horst, Liora, Bulle, Esther B, van Baarle, Frank E H P, van de Poll, Marcel C G, Kemper, E Marleen, van der Horst, Iwan C C, Schultz, Marcus J, Horn, Janneke, Paulus, Frederique, Bos, Lieuwe D, Wiersinga, W Joost, Witzenrath, Martin, Rueckinger, Simon, Pilz, Korinna, Brouwer, Matthijs C, Guo, Ren-Feng, Heunks, Leo, van Paassen, Pieter, Riedemann, Niels C, van de Beek, Diederik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521913/
https://www.ncbi.nlm.nih.gov/pubmed/33015643
http://dx.doi.org/10.1016/S2665-9913(20)30341-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521913/
https://www.ncbi.nlm.nih.gov/pubmed/33015643
http://dx.doi.org/10.1016/S2665-9913(20)30341-6

Ejemplares similares